Loading news...
Incyte started 2026 on a high note. On January 7, its stock hit an all-time high of $112.29. In my view, the key drivers of raised investor interest in Incyte are the strong performance of its ruxolitinib franchise.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 am (EST) Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10, 2026 at 9:20 am (EDT) and Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 at 8:30 am (EDT) The presentations will be webcast live and can be accessed.
Cookson Peirce and Co. Inc. bought a new stake in Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,331 shares of the biopharmaceutical company's stock, valued at approximately $961,000. A number of other hedge funds have also
Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quarter results that beat consensus estimates, raising full-year operating profit guidance by 10% on demand recovery and improved utilization rates. Sea Limited reported September quarter results that beat consensus estimates, with revenue growing 38% and gross merchandise value growing 28%.
Incyte (NASDAQ: INCY) executives highlighted stronger-than-expected 2025 commercial performance, an increasingly late-stage pipeline, and multiple regulatory milestones during the company's fourth quarter and year-end 2025 financial results conference call. 2025 results exceeded expectations Chief Executive Officer Bill presented a summary of 2025 performance, noting that the company "exceeded expectations" on total sales, Jakafi sales, and core
Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Adjusted for royalties, INCY's 2026 sales guidance is nearly in line with expectations, representing 11.5% YoY growth in Net Product Sales. Opzelura sales guidance was slightly below consensus, but the ex-Jakafi portfolio is growing rapidly, supporting a robust long-term outlook.
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Release Date: February 10, 2026For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Incyte Corp
Incyte posts a Q4 EPS miss but a 28% revenue jump, fueled by Jakafi and Opzelura strength, as product sales top estimates.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) came out with quarterly earnings of $1.8 per share, missing the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.43 per share a year ago.
Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming patent losses on top-seller Jakafi.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Fourth Quarter and Full Year 2025 Financial Results.
Profund Advisors LLC cut its position in shares of Incyte Corporation (NASDAQ: INCY) by 28.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,465 shares of the biopharmaceutical company's stock after selling 8,689 shares during the quarter. Profund
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Azzad Asset Management Inc. ADV bought a new position in shares of Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,196 shares of the biopharmaceutical company's stock, valued at approximately $1,374,000. Other institutional investors also
Candriam S.C.A. lowered its stake in Incyte Corporation (NASDAQ: INCY) by 26.9% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 753,332 shares of the biopharmaceutical company's stock after selling 277,789 shares during the period. Candriam S.C.A. owned 0.38% of Incyte worth $63,890,000
INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Incyte (INCY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.